As of Friday close, Catalyst Pharmaceuticals Inc.’s (NASDAQ:CPRX) stock was up $0.36, moving up 3.34 percent to $11.13. The average number of shares traded per day over the past five days has been 1,590,540 shares. 5 times new highs have been achieved over the past 5 days, with a $0.89 gain in that time frame. In the last twenty days, the average volume was 2,141,975, while in the previous 50 days, it was 1,552,170.
Since last month, CPRX stock rose 46.06%. Shares of the company fell to $7.35 on 07/06/22, the lowest level in the past month. A 52-week high of $10.91 was reached on 08/05/22 after having rallying from a 52-week low of $4.81. Since the beginning of this year, CPRX’s stock price has risen by 64.40% or $4.36, and marked a new high 27 times. However, the stock has increased by 2.02% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Catalyst Pharmaceuticals Inc. (CPRX) last reported insider trading activity 45 days ago on Jun 22. INGENITO GARY, the Chief Medical & Reg. Officer of the company, disposed of 6,152 shares for $6.61 on Jun 22. It resulted in a $40,646 divestment by the insider. INGENITO GARY sold 143,848 shares at an average price of $6.59 on Jun 21. The insider now owns 22,053 shares following the transaction. On Dec 07, Chief Medical Officer INGENITO GARY sold 3,612 shares at $6.99 apiece. The transaction was valued at $25,237.
Right now, Catalyst Pharmaceuticals Inc. (CPRX) has a P/E ratio of about 26.75. The stock’s beta is 1.44. Besides these, the trailing price-to-sales (P/S) ratio of 7.56, the price-to-book (PB) ratio of 5.20.
In the three months ended March 30, Catalyst Pharmaceuticals Inc.’s quick ratio stood at 9.30, while its current ratio was 9.60, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 85.00% percent. In the year ended March 30, operating margins totaled 39.10%. Based on annual data, CPRX earned $118.95 million in gross profit and brought in $140.83 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 19.00%. Return on equity (ROE) for the past 12 months was 22.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. CPRX’s revenue rose 29.89% to $38.31 million during the quarter, while net income inched up to $43.09 million. While analysts expected Catalyst Pharmaceuticals Inc. to report $0.14 quarterly earnings, the actual figure was $0.12 per share, beating the consensus estimate by -14.30%. During the quarter, the company generated $17.4 million in EBITDA. The liabilities of Catalyst Pharmaceuticals Inc. were 26.75 million at the end of its most recent quarter ended March 30, and its total debt was $4.13 million. The value of shareholders’ equity is $102.78 million.
This quick technical analysis looks at Catalyst Pharmaceuticals Inc.’s (CPRX) price momentum. With a historical volatility rate of 33.35%, the RSI 9-day stood at 81.08% on 05 August.
With respect to its five-day moving average, the current Catalyst Pharmaceuticals Inc. price is up by +8.69% percent or $0.89. At present, CPRX shares trade +47.22% above its 20-day simple moving average and +45.87% percent above its 100-day simple moving average. However, the stock is currently trading approximately +62.01% above its SMA50 and +84.58% above its SMA200.
Stochastic coefficient K was 92.81% and Stochastic coefficient D was 90.66%, while ATR was 0.50. Given the Stochastic reading of 98.39% for the 14-day period, the RSI (14) reading has been calculated as 78.85%. As of today, the MACD Oscillator reading stands at 0.30, while the 14-day reading stands at 0.61.
Cantor Fitzgerald launched its rating on Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) to an Overweight in a note to investors on September 21, 2018. Catalyst Pharmaceuticals Inc. (CPRX) has been rated Buy by analysts. According to 0 brokerage firms, CPRX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Catalyst Pharmaceuticals Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $12.00, the current consensus forecast for the stock is $9.00 – $15.00. Based on these forecasts, analysts predict Catalyst Pharmaceuticals Inc. (CPRX) will achieve an average price target of $11.60.